Literature DB >> 11578752

Standardization of micro-enzyme-linked immunosorbent assay (ELISA) and Western blot for detection of Trypanosoma cruzi antibodies using extracts from Mexican strains as antigens.

B Sánchez1, V Monteón, P A Reyes, B Espinoza.   

Abstract

BACKGROUND: This report describes two assays for the detection of anti-Trypanosoma cruzi antibodies using Mexican strains of the parasite and the concordance with two assays previously evaluated at the Instituto Nacional de Cardiología Ignacio Chávez in Mexico City.
METHODS: Micro-enzyme-linked immunosorbent assay (ELISA) and Western blot were used for the detection of T. cruzi antibodies with a total extract of epimastigote from Ninoa and Queretaro, which are Mexican strains of T. cruzi. To standardize these methods, a total of 246 serum samples was used. In addition, sera from six confirmed Mexican chronic individuals in the asymptomatic phase were also used for comparison with the Argentinean antigen.
RESULTS: ELISA was 100% specific in that no false positive results were found with sera of both healthy individuals and non-Chagasic cardiopaths. Sera from individuals infected with Leishmania sp. showed approximately 16% of cross-reaction with ELISA. The test showed a positive predictive value of 90% and a negative predictive value of 100%. Western blot was also a highly sensitive test for detecting chronic Chagasic symptomatic patients from Mexico because no false negative results were obtained. Furthermore, it was possible to use Western blot to detect seven immunodominant antigens of approximately 30, 32, 40, 42, 65, 70, and 83 kDa. Concordance with two previous standardized tests at the Instituto Nacional de Cardiología showed a Kappa index of 0.96, indicating high concordance between the results obtained at these two laboratories. Finally, ELISA using Ninoa antigen extract was more sensitive than ELISA with an Argentinean extract, which failed to detect individuals in the chronic asymptomatic phase (undetermined phase) of infection.
CONCLUSIONS: This study indicates that ELISA and Western blot using Ninoa and/or Queretaro extracts of T. cruzi as antigens are useful tools in the detection of individuals who have been exposed to T. cruzi both in the undetermined/asymptomatic and symptomatic phases. More concordance studies such as this are recommended to obtain an accurate Chagas diagnostic test and to determine the real prevalence of this disease in Mexico.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578752     DOI: 10.1016/s0188-4409(01)00303-4

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  14 in total

1.  Identification of a Western blot pattern for the specific diagnosis of Trypanosoma cruzi infection in human sera.

Authors:  Cristina Riera; Mireia Verges; Laura Iniesta; Roser Fisa; Montserrat Gállego; Silvia Tebar; Montserrat Portús
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

2.  Identification of a hyperendemic area for Trypanosoma cruzi infection in central Veracruz, Mexico.

Authors:  Angel Ramos-Ligonio; Aracely López-Monteon; Daniel Guzmán-Gómez; José Luis Rosales-Encina; Yairh Limón-Flores; Eric Dumonteil
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

3.  Immunological identification of Trypanosoma cruzi lineages in human infection along the endemic area.

Authors:  Marikena G Risso; Paula A Sartor; Juan M Burgos; Luis Briceño; Eva M Rodríguez; Felipe Guhl; Omar Triana Chavez; Berta Espinoza; Victor M Monteón; Graciela Russomando; Alejandro G Schijman; Oscar A Bottasso; Maria Susana Leguizamón
Journal:  Am J Trop Med Hyg       Date:  2011-01       Impact factor: 2.345

4.  Do commercial serologic tests for Trypanosoma cruzi infection detect Mexican strains in women and newborns?

Authors:  Rubi Gamboa-León; Claudia Gonzalez-Ramirez; Nicolas Padilla-Raygoza; Sergio Sosa-Estani; Alejandra Caamal-Kantun; Pierre Buekens; Eric Dumonteil
Journal:  J Parasitol       Date:  2010-10-21       Impact factor: 1.276

5.  Increased myeloperoxidase activity and protein nitration are indicators of inflammation in patients with Chagas' disease.

Authors:  Monisha Dhiman; Jose Guillermo Estrada-Franco; Jasmine M Pando; Francisco J Ramirez-Aguilar; Heidi Spratt; Sara Vazquez-Corzo; Gladys Perez-Molina; Rosa Gallegos-Sandoval; Roberto Moreno; Nisha Jain Garg
Journal:  Clin Vaccine Immunol       Date:  2009-03-18

6.  Mexican Trypanosoma cruzi T. cruzi I strains with different degrees of virulence induce diverse humoral and cellular immune responses in a murine experimental infection model.

Authors:  B Espinoza; T Rico; S Sosa; E Oaxaca; A Vizcaino-Castillo; M L Caballero; I Martínez
Journal:  J Biomed Biotechnol       Date:  2010-04-11

7.  Regional variation in the correlation of antibody and T-cell responses to Trypanosoma cruzi.

Authors:  Diana L Martin; Morgan Marks; Gerson Galdos-Cardenas; Robert H Gilman; Brook Goodhew; Lisbeth Ferrufino; Anthony Halperin; Gerardo Sanchez; Manuela Verastegui; Patricia Escalante; Cesar Naquira; Michael Z Levy; Caryn Bern
Journal:  Am J Trop Med Hyg       Date:  2014-04-07       Impact factor: 2.345

Review 8.  ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis.

Authors:  Pedro E A A Brasil; Liane De Castro; Alejandro M Hasslocher-Moreno; Luiz H C Sangenis; José U Braga
Journal:  BMC Infect Dis       Date:  2010-11-25       Impact factor: 3.090

9.  High molecular weight proteins of Trypanosoma cruzi reduce cross-reaction with Leishmania spp. in serological diagnosis tests.

Authors:  Alejandra Yunuen Cervantes-Landín; Ignacio Martínez; Muslim Schabib; Bertha Espinoza
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

10.  Chagas Disease Infection among Migrants at the Mexico/Guatemala Border.

Authors:  Erin E Conners; Teresa López Ordoñez; Celia Cordon-Rosales; Carmen Fernández Casanueva; Sonia Morales Miranda; Kimberly C Brouwer
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.